Home Management of perinatal HPP during critical illness/ECMO
Article
Licensed
Unlicensed Requires Authentication

Management of perinatal HPP during critical illness/ECMO

  • Neetu Krishnan EMAIL logo and Nancy Dunbar
Published/Copyright: September 28, 2021

Abstract

Objectives

With the advent of asfotase alfa, the enzyme replacement therapy (ERT) approved for hypophosphatasia (HPP), health care providers need to navigate management of ERT during critical illness.

Case presentation

We present the case of a young girl, treated with ERT for severe perinatal HPP, who had cardiorespiratory arrest in the setting of influenza A. Her life-saving treatment involving extra corporeal membrane oxygenation (ECMO) required a two-week interruption of ERT leading to persistent hypercalcemia and hyperphosphatemia. A three year old female presented with respiratory distress and blood tinged secretions. She was influenza A positive with bilateral opacities on chest X-ray (CXR). Worsening respiratory distress and bradycardic arrest required intubation, CPR and venoarterial ECMO cannulation. She remained on ECMO for 10 days with anticoagulation restrictions requiring her thrice-weekly subcutaneous ERT to be held. Hypercalcemia (12.3 mg/dL) and hyperphosphatemia (7.6 mg/dL) developed two weeks after restarting ERT and resolved six weeks later.

Conclusions

We highlight that the obligatory cessation of ERT while on ECMO led to the loss of functional TNSALP with a profound decrease in bone mineralization leading to excess circulating calcium and phosphorus. In cases where it is necessary to interrupt ERT, we advise close monitoring of calcium and phosphorous levels.


Corresponding author: Neetu Krishnan, DO, Department of Pediatric Endocrinology, Connecticut Children’s, 505 Farmington Avenue, Farmington, CT, 06032, USA, Phone: 860 837 6700, Fax: 860 837 6765, E-mail:

  1. Research funding: None declared.

  2. Author contributions: All authors have accepted responsibility for the entire content of this manuscript and approved its submission.

  3. Competing interests: ND is on the speaker bureau for Alexion and has been a consultant for them in the past.

  4. Informed consent: Informed consent was obtained from all individuals included in this study.

  5. Ethical approval: The local Institutional Review Board deemed the study exempt from review.

References

1. Whyte, M, Leung, E, Wilcox, W, Liese, J, Argente, J, Martos-Moreno, GÁ, et al.. Natural history of perinatal and infantile hypophosphatasia: a retrospective study. J Pediatr 2019;209:116–24. https://doi.org/10.1016/j.jpeds.2019.01.049.Search in Google Scholar

2. Whyte, M, Rockman-Greenberg, C, Ozono, K, Riese, R, Moseley, S, Thrompson, D, et al.. Asfotase alfa treatment improves survival for perinatal and infantile hypophosphatasia. J Clin Endocrinol Metab 2016;101:334–42. https://doi.org/10.1210/jc.2015-3462.Search in Google Scholar

3. Hofmann, C, Harmatz, P, Vockley, J, Högler, W, Nakayama, H, Bishop, N, et al.. Efficacy and safety of asfotase alfa in infants and young children with hypophosphatasia: a phase 2 open-label study. J Clin Endocrinol Metab 2019;104:2735–47. https://doi.org/10.1210/jc.2018-02335.Search in Google Scholar

4. Whyte, M, Simmons, J, Moseley, S, Fujita, K, Bishop, N, Salman, N, et al.. Asfotase alfa for infants and young children with hypophosphatasia: 7 year outcomes of a single-arm, open-label, phase 2 extension trial. Lancet Diabetes Endocrinol 2019;7:93–105. https://doi.org/10.1016/s2213-8587(18)30307-3.Search in Google Scholar

5. Mulder, M, Fawzy, I, Lance, M. ECMO and anticoagulation: a comprehensive review. Neth J Crit Care 2018;26:6–13.Search in Google Scholar

6. Pan, W, Pradhan, R, Pelto, R, Seefried, L. Pharmacokinetics of asfotase alfa in adult patients with pediatric-onset hypophosphatasia. J Clin Pharmacol 2021;61:1334–43. https://doi.org/10.1002/jcph.1870.Search in Google Scholar PubMed PubMed Central

Received: 2021-03-26
Accepted: 2021-09-06
Published Online: 2021-09-28
Published in Print: 2022-01-27

© 2021 Walter de Gruyter GmbH, Berlin/Boston

Articles in the same Issue

  1. Frontmatter
  2. Review Article
  3. Medullary thyroid carcinoma in children: current state of the art and future perspectives
  4. Original Articles
  5. Newly defined peroxisomal disease with novel ACBD5 mutation
  6. Pediatric adrenocortical tumors cohort characteristics and long-term follow-up at a single Argentinian tertiary center
  7. Sleep disorder and behavior problems in children with type 1 diabetes mellitus
  8. Increased hepcidin levels and non-alcoholic fatty liver disease in obese prepubertal children: a further piece to the complex puzzle of metabolic derangements
  9. Screening for testicular adrenal rest tumors among children with congenital adrenal hyperplasia at King Fahad Medical City, Saudi Arabia
  10. The association between vitamin D levels and metabolic syndrome components among metropolitan adolescent population
  11. Utility of wrist circumference in recognition of metabolic syndrome in overweight and obese South Indian children and adolescents
  12. Ketoacidosis in new-onset type 1 diabetes: did the severity increase during the COVID-19 pandemic?
  13. Predictors of decreased bone mineral density in childhood systemic lupus erythematosus: possible role of osteoprotegerin gene polymorphisms
  14. Psychiatric behavioral effect and characteristics of type 2 diabetes mellitus on Japanese patients with Prader-Willi syndrome: a preliminary retrospective study
  15. Biochemical predictors of metabolically unhealthy obesity in children and adolescents
  16. Adiposity rebound in very-low-birth-weight infants
  17. The association between a metabolically healthy overweight/obesity phenotype and markers of inflammation among Chinese children and adolescents aged 10–18 years
  18. Case Reports
  19. Management of perinatal HPP during critical illness/ECMO
  20. Wolfram-like syndrome – another face of a rare disease in children
  21. Two Japanese siblings with arginase-1 deficiency identified using a novel frameshift mutation of ARG1 (p.Lys41Thrfs2)
  22. An atypical presentation of a pathogenic STK11 gene variant in siblings not fulfilling the clinical diagnostic criteria for Peutz-Jeghers Syndrome
Downloaded on 17.9.2025 from https://www.degruyterbrill.com/document/doi/10.1515/jpem-2021-0187/html
Scroll to top button